|
1
|
Yusup A, Wang HJ, Rahmutula A, Sayim P,
Zhao ZL and Zhang GQ: Clinical features and prognosis in colorectal
cancer patients with different ethnicities in Northwest China.
World J Gastroenterol. 19:7183–7188. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chauvin A, Wang CS, Geha S, Garde-Granger
P, Mathieu AA, Lacasse V and Boisvert FM: The response to
neoadjuvant chemoradiotherapy with 5-fluorouracil in locally
advanced rectal cancer patients: A predictive proteomic signature.
Clin Proteomics. 15:162018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mao L, Li Y, Zhao J, Li Q, Yang B, Wang Y,
Zhu Z, Sun H and Zhai Z: Transforming growth factor-β1 contributes
to oxaliplatin resistance in colorectal cancer via epithelial to
mesenchymal transition. Oncol Lett. 14:647–654. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kunigou O, Nagao H, Kawabata N, Ishidou Y,
Nagano S, Maeda S, Komiya S and Setoguchi T: Role of GOLPH3 and
GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep.
26:1337–1342. 2011.PubMed/NCBI
|
|
5
|
Zhang LJ, Wang KB, Liu LS, Chen LZ, Peng
BG, Liang LJ, Li Z, Xue L, Li W and Xia JT: Overexpression of
GOLPH3 is associated with poor prognosis and clinical progression
in pancreatic ductal adenocarcinoma. BMC Cancer. 14:5712014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xue Y, Wu G, Liao Y, Xiao G, Ma X, Zou X,
Zhang G, Xiao R, Wang X, Liu Q, et al: GOLPH3 is a novel marker of
poor prognosis and a potential therapeutic target in human renal
cell carcinoma. Br J Cancer. 110:2250–2260. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma Y, Wang X, Wu Y, Sun B, Lv H, Rong F
and Zheng X: Overexpression of GOLPH3 protein is associated with
worse prognosis in patients with epithelial ovarian cancer. Tumour
Biol. 35:11845–11849. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li W, Qi K and Wang Z, Gu M, Chen G, Guo F
and Wang Z: Golgi phosphoprotein 3 regulates metastasis of prostate
cancer via matrix metalloproteinase 9. Int J Clin Exp Pathol.
8:3691–3700. 2015.PubMed/NCBI
|
|
9
|
Zhou ZP, Qiu CZ and Yu WS: Relationship
between golgi phosphoprotein 3 expression and Wnt/β-catenin
signaling in colorectal cancer tissue. Chin J Exp Surg.
30:2709–2710. 2013.
|
|
10
|
Qiu CZ, Wang MZ, Yu WS, Guo YT, Wang CX
and Yang XF: Correlation of GOLPH3 gene with Wnt signaling pathway
in human colon cancer cells. J Cancer. 7:928–934. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hato SV, Khong A, de Vries IJ and
Lesterhuis WJ: Molecular pathways: The immunogenic effects of
platinum-based chemotherapeutics. Clin Cancer Res. 20:2831–2837.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dilruba S and Kalayda GV: Platinum-based
drugs: Past, present and future. Cancer Chemother Pharmacol.
77:1103–1124. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hatch SB, Swift LP, Caporali S, Carter R,
Hill EJ, MacGregor TP, D'Atri S, Middleton MR, McHugh PJ and Sharma
RA: XPF protein levels determine sensitivity of malignant melanoma
cells to oxaliplatin chemotherapy: Suitability as a biomarker for
patient selection. Int J Cancer. 134:1495–1503. 2014. View Article : Google Scholar :
|
|
14
|
Sun Y, Wu Y, Li W, Kong Z and Zou X:
Genetic polymorphisms in nucleotide excision repair pathway
influences response to chemotherapy and overall survival in
osteosarcoma. Int J Clin Exp Pathol. 8:7905–7912. 2015.PubMed/NCBI
|
|
15
|
Sawers L, Ferguson MJ, Ihrig BR, Young HC,
Chakravarty P, Wolf CR and Smith G: Glutathione S-transferase P1
(GSTP1) directly influences platinum drug chemosensitivity in
ovarian tumour cell lines. Br J Cancer. 111:1150–1158. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ye H, Shao M, Shi X, Wu L, Xu B, Qu Q and
Qu J: Predictive assessment in pharmacogenetics of Glutathione
S-transferases genes on efficacy of platinum-based chemotherapy in
non-small cell lung cancer patients. Sci Rep. 7:26702017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu L, Bai Z, Ma X, Wang T, Yang Y and
Zhang Z: Effects of taxol resistance gene 1 expression on the
chemosensitivity of SGC-7901 cells to oxaliplatin. Exp Ther Med.
11:846–852. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gao H, Song X, Kang T, Yan B, Feng L, Gao
L, Ai L, Liu X, Yu J and Li H: Long noncoding RNA CRNDE functions
as a competing endogenous RNA to promote metastasis and oxaliplatin
resistance by sponging miR-136 in colorectal cancer. OncoTargets
Ther. 10:205–216. 2017. View Article : Google Scholar
|
|
19
|
Huang BY, Zeng Y, Li YJ, Huang XJ, Hu N,
Yao N, Chen MF, Yang ZG, Chen ZS, Zhang DM, et al: Uncaria
alkaloids reverse ABCB1-mediated cancer multidrug resistance. Int J
Oncol. 51:257–268. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tarapcsák S, Szalóki G, Telbisz Á, Gyöngy
Z, Matúz K, Csősz É, Nagy P, Holb IJ, Rühl R, Nagy L, et al:
Interactions of retinoids with the abc transporters p-glycoprotein
and breast cancer resistance protein. Sci Rep. 7:413762017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang J, Zhang K, Wu J, Shi J, Xue J, Li J,
Chen J, Zhu Y, Wei J, He J and Liu X: Wnt5a increases properties of
lung cancer stem cells and resistance to cisplatin through
activation of wnt5a/pkc signaling pathway. Stem Cells Int.
2016:16908962016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Miao Y, Zheng W, Li N, Su Z, Zhao L, Zhou
H and Jia L: MicroRNA-130b targets PTEN to mediate drug resistance
and proliferation of breast cancer cells via the PI3K/Akt signaling
pathway. Sci Rep. 7:419422017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xi R, Pan S, Chen X, Hui B, Zhang L, Fu S,
Li X, Zhang X, Gong T, Guo J, et al: Hpv16 e6-e7 induces cancer
stem-like cells phenotypes in esophageal squamous cell carcinoma
through the activation of pi3k/akt signaling pathway in vitro and
in vivo. Oncotarget. 7:57050–57065. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shen L, Yang M, Lin Q, Zhang Z, Miao C and
Zhu B: SKA1 regulates the metastasis and cisplatin resistance of
non-small cell lung cancer. Oncol Rep. 35:2561–2568. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Son DJ, Hong JE, Ban JO, Park JH, Lee HL,
Gu SM, Hwang JY, Jung MH, Lee DW, Han SB, et al: Synergistic
inhibitory effects of cetuximab and cisplatin on human colon cancer
cell growth via inhibition of the erk-dependent egf receptor
signaling pathway. BioMed Res Int. 2015:3975632015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu W, Zhang Z, Zhang Y, Chen X, Guo S,
Lei Y, Xu Y, Ji C, Bi Z and Wang K: HMGB1-mediated autophagy
modulates sensitivity of colorectal cancer cells to oxaliplatin via
MEK/ERK signaling pathway. Cancer Biol Ther. 16:511–517. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao W, Liu S, Dou Q, Li C, Du J and Ren
W: The role and mechanism of WEE1 on the cisplatin resistance
reversal of the HepG2/DDP human hepatic cancer cell line. Oncol
Lett. 10:3081–3086. 2015. View Article : Google Scholar
|
|
28
|
Farber-Katz SE, Dippold HC, Buschman MD,
Peterman MC, Xing M, Noakes CJ, Tat J, Ng MM, Rahajeng J, Cowan DM,
et al: DNA damage triggers Golgi dispersal via DNA-PK and GOLPH3.
Cell. 156:413–427. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Buschman MD, Rahajeng J and Field SJ:
GOLPH3 links the Golgi, DNA damage, and cancer. Cancer Res.
75:624–627. 2015. View Article : Google Scholar : PubMed/NCBI
|
